Expert review of the data and presentation of different approaches to complex cases would help clinicians appreciate the range of clinical practice across NCCN Member Institutions, and highlight key considerations when presenting patients with options for treatment.
These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.
Since immune checkpoint inhibitors and BRAF targeted therapies are now available, there are many patients with advanced melanoma who are surviving multiple lines of treatment, so the complexity of cases is increasing.
Since immune checkpoint inhibitors and BRAF targeted therapies are now available, there are many patients with advanced melanoma who are surviving multiple lines of treatment, so the complexity of cases is increasing.
The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body.
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Several new adjuvant systemic therapy options for adjuvant treatment of stage III melanoma were added to the melanoma guidelines in v2018, such that there are now multiple adjuvant systemic therapy options in some settings.
Join Cindy L. O’Bryant, PharmD, from the University of Colorado Cancer Center for this webinar in the 2018 NCCN Pharmacy Update Series on the topic Treatment Considerations in Metastatic Melanoma.
Facebook
Twitter
LinkedIn
Forward
